Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11103345 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL8438902 | 0.77 | MIF (0.37) | MIF | |
| Hydrochloric Acid SCHEMBL31551433 | 0.75 | SLC7A5 (0.39) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL29706081 | 0.75 | MIF (0.42) | MIFSMN1; SMN2TSHRELANECA14 | |
| Hydrochloric Acid SCHEMBL30838779 | 0.72 | MIF (0.41) | MIFELANECA14 | |
| SCHEMBL331491 | 0.72 | — | — | |
| SCHEMBL13931313 | 0.71 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRCA12CA1CA2 | |
| SCHEMBL11809884 | 0.71 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRCA12CA1CA2 | |
| SCHEMBL128484 | 0.71 | — | — | |
| SCHEMBL8323403 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022168106-A1 | CHEMO-ENZYMATIC PROCESS FOR SYNTHESIS OF MOLNUPIRAVIR | FERMENTA BIOTECH LIMITED (IN) | 2022-08-11 | — | — | WO | claimed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163262-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-112608357-B | Preparation method of antiviral drug Molnbupiravir | 杭州科巢生物科技有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2022208508-A1 | SCALABLE TWO STEP SYNTHESIS OF MOLNUPIRAVIR | FERMENTA BIOTECH LIMITED (IN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022168106-A1 | CHEMO-ENZYMATIC PROCESS FOR SYNTHESIS OF MOLNUPIRAVIR | FERMENTA BIOTECH LIMITED (IN) | 2022-08-11 | — | — | WO | disclosed |
| US-11407779-B1 | Process for the preparation of molnupiravir | DIVI'S LABORATORIES LTD. (IN) | 2022-08-09 | — | — | US | disclosed |
| CN-112608357-A | Preparation method of antiviral drug Molnbupiravir | 杭州科巢生物科技有限公司 | 2021-04-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407779-B1 | Process for the preparation of molnupiravir | ALKBH1, ALKBH5, ALKBH3 | MIF 422/4885SMN1; SMN2 2809/4885TSHR 1552/4885 |
| US-20230015308-A1 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | WEE1, CBR3, GLRX3 | MIF 3962/4885SMN1; SMN2 4661/4885TSHR 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.